Mesothelial cells (MC) are the first peritoneal membrane barrier in contact with dialysate. The aim of this study was to analyze the in vitro capacity of different pharmacological agents to modify the ex vivo proliferation of MC obtained from the peritoneal effluent of @entity1 treated with @entity298 ( @entity298 ). MATERIAL AND METHODS: Thirty cultures of MC taken from nocturnal peritoneal effluent were performed. After identification, MC are subcultured in 24 multi-well plates, adding the different exogenous agents. Proliferative capacity and cell morphology were estimated on day 16th of culture. The agents evaluated were insulin, @entity442 , @entity440 , @entity6555 , @entity1405 , @entity4688 and @entity9886 . RESULTS: Insulin shows a dose-dependent effect on MC growth, with a limit that is stimulated by the addition of @entity2241 ( @entity2241 ). Concentrations higher than 100 micrograms/ml, are not associated with further growth, even with cell damage. In contrast, the wide range of @entity442 dose used did not affect to MC proliferation. @entity440 causes negative effects on MC growth just a very high doses, not resembling doses in clinical practice. @entity6555 does not modify MC proliferation used under therapeutic calculated range. However, concentrations higher than 40 micrograms/ml showed a negative influence on growth, behaving as lethal doses that over 100 micrograms/ml. The addition of @entity2241 attenuates this effect. These effects were very similar to that caused by @entity1405 addition. @entity4688 and @entity9886 act as antiproliferative agents for MC. This effect is potentiated with @entity2178 , reaching lethal concentrations increasing the dose. In conclusion, mesothelial cell growth ex vivo taken from nocturnal peritoneal effluent on @entity298 @entity1 is an useful tool to explore the effects of any pharmacological agent on the biology of the cell of the peritoneum. The agents used had any influence in the proliferation capacity of mesothelial cells.

[Influence of different pharmacological agents in the ex vivo proliferation of mesothelial cells obtained from the peritoneal effluent of XXXX treated with @entity298 ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4688 :: ('MESH:D004656', 'Chemical') :: ['enalapril', 'Enalapril'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen', 'Tamoxifen'] @entity6555 :: ('MESH:D007741', 'Chemical') :: ['Labetalol', 'labetalol'] @entity2178 :: ('183', 'Gene') :: ['angiotensin II'] @entity442 :: ('3479', 'Gene') :: ['IGF-1'] @entity1405 :: ('MESH:C043211', 'Chemical') :: ['carvedilol'] @entity9886 :: ('MESH:D019808', 'Chemical') :: ['losartan'] @entity298 :: ('MESH:D010538', 'Disease') :: ['peritoneal dialysis', 'PD'] @entity2241 :: ('MESH:D005315', 'Disease') :: ['FBS', 'fetal bovine serum']
@entity1 :: (9606,Species) :: ['patients']
